>> FIRST ACHIEVEMENTS
1954: Set up of the affiliated Gobbi L.L.C [Limited Liability Company], dedicated to the manufacture of radiology products. Being the only industrial plant in Latin America capable of carrying out chemical synthesis for the production of contrast agents for radiology.
1958: Acquisition of a factory in Wilde, which is refurbished to build the new industrial plant.
1962: Gobbi Commercial Industrial Corporation converts itself in the sole representative of R.I.T (Belgium) for the import of Salk and Oral Sabin polio vaccines.
>> LEADERSHIP CONSOLIDATION
1969: Ferrer Laboratories from Spain buys the 51% of the shares of Gobbi Commercial Industrial Corporation and becomes Gobbi Novag S.A [Corporation]. Ferrer Laboratories also gives to Gobbi Novag S.A. the sole representation of the products line made out of Metronidazole; Bexon Oral and Bexon Vaginal medical products, which reach a great acceptance by the physicians, and are being commercialized nowadays.
1972: The nucleus CMP, an advanced neurochemistry regenerator, is launched to the market, reaching a huge impact in the medical community.
1975: Ferrer Laboratories sells the 100% of its shares to the current shareholders of the company.
1980: Gobbi Novag S.A. launches to the market Triyosom Tomográfico [Triyosom], which is the first oral contrast agent for tomography in the world.
1987: Irigal is added to the ethical product line of Gobbi Novag S.A., as the first anti-inflammatory, antibiotic, anaesthetic and cicatrizing spray on the market.
>> NEW MARKETS RESEARCH
1991: The laboratory expands to over-the-counter (OTC) products launching Natuvit (dietary fibre), its first great success in its market.
1994: Gobbi Novag enters in the skin care market, launching Imedeen in Argentina, which becomes the second product in sales of the OTC market.
1996: Snell Progress is added to the OTC line. Imported from Italy, as the first anti-cellulite product in occlusive patches.
>> A NEW ERA BEGINS
1998: Gobbi Novag S.A. incorporates the oncology products division, becoming the sole distributor of the original Cyproterone Androcur 50 and 100 mg from Schering AG.
1999: Gobbi Novag S.A. enters into the anaesthetic market, importing Recofol from Leiras Oy as its sole representative. Thus it begins a new stage in the life of the laboratory.
2000: Gobbi Novag S.A. launches Aclosan (first generic Tamsulosin) with its own development.
2003: Gobbi agrees with Baxter the marketing of Protromplex in the hospital market.
2004: Gobbi agrees with Pfizer the promotion of the oncology line.
Gobbi agrees with Jansen Cilag promotion of its product Velcade, reaching a sales record in Latin and Central America.
2005: Gobbi Novag S.A. launches in Argentina the first Mepivacaine.
2006: Re-launching of Infukoll Hes 6% (starch), manufactured in their own facilities.